We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+15.02%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.99B
AUM Growth
+$445M
Cap. Flow
-$204M
Cap. Flow %
-5.12%
Top 10 Hldgs %
26.88%
Holding
133
New
39
Increased
28
Reduced
23
Closed
37

Top Sells

Rank Stock Value
1
RRC icon
Range Resources
RRC
+$86.2M
2
CI icon
Cigna
CI
+$69.3M
3
CRM icon
Salesforce
CRM
+$63M
4
ZAYO
Zayo Group Holdings, Inc.
ZAYO
+$61.7M
5
BIIB icon
Biogen
BIIB
+$55.1M

Sector Composition

Rank Sector Weight
1 Healthcare 38.53%
2 Technology 10.63%
3 Communication Services 6.21%
4 Energy 4.56%
5 Consumer Discretionary 4.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HOLX
26
DELISTED
Hologic
HOLX
$51.6M 1.29%
1,213,261
+159,474
+15% +$6.5M
UNH icon
27
UnitedHealth
UNH
$382B
$51.4M 1.29%
313,398
-214,167
-41% -$35.1M
LLY icon
28
Eli Lilly
LLY
$1.07T
$48.4M 1.21%
+575,249
New +$46.1M
VISN
29
Vistance Networks Inc
VISN
$2.66B
$47.6M 1.19%
1,142,225
+469,458
+70% +$18.1M
META icon
30
Meta Platforms (Facebook)
META
$1.51T
$47.4M 1.19%
333,491
+37,487
+13% +$5.01M
PANW icon
31
Palo Alto Networks
PANW
$264B
$44.1M 1.1%
2,345,646
+798,174
+52% +$17.8M
AKRX
32
DELISTED
Akorn Inc
AKRX
$43.8M 1.1%
+1,817,174
New +$39.5M
CI icon
33
Cigna
CI
$76.6B
$43.2M 1.08%
294,596
-470,213
-61% -$69.3M
EW icon
34
Edwards Lifesciences
EW
$47.6B
$43M 1.08%
1,370,298
-1,211,871
-47% -$37.9M
SLB icon
35
SLB Ltd
SLB
$77.8B
$42.9M 1.07%
+549,389
New +$44.9M
SPLK
36
DELISTED
Splunk Inc
SPLK
$42.5M 1.06%
+682,657
New +$40.8M
SPNC
37
DELISTED
Spectranetics Corp
SPNC
$42.3M 1.06%
1,451,030
+85,085
+6% +$2.27M
SCHW
38
Charles Schwab
SCHW
$177B
$42.2M 1.06%
1,033,855
+510,467
+98% +$21.1M
BPMC
39
DELISTED
Blueprint Medicines
BPMC
$42.1M 1.05%
1,052,012
+252,061
+32% +$9.03M
OEF icon
40
CALL
iShares S&P 100 ETF
OEF
$19.8B
$40.3M 1.01%
+137,400
New +$14.2M
PBYI icon
41
Puma Biotechnology
PBYI
$406M
$39.6M 0.99%
1,065,356
-78,332
-7% -$2.86M
ATHN
42
DELISTED
Athenahealth, Inc.
ATHN
$38.6M 0.97%
+342,540
New +$39.9M
ANDV
43
DELISTED
Andeavor
ANDV
$37.4M 0.94%
+460,878
New +$38.6M
HAIN icon
44
Hain Celestial
HAIN
$47.8M
$36.8M 0.92%
989,755
-1,040,847
-51% -$39.2M
AAPL icon
45
Apple
AAPL
$4.89T
$36.2M 0.91%
+1,008,128
New +$33.2M
NTES icon
46
NetEase
NTES
$76.5B
$36M 0.9%
+633,430
New +$34.1M
ABBV icon
47
AbbVie
ABBV
$458B
$34.3M 0.86%
526,354
-645,013
-55% -$40.6M
UNP icon
48
Union Pacific
UNP
$183B
$31.7M 0.79%
299,502
-495,048
-62% -$52.8M
CHRS icon
49
Coherus Oncology
CHRS
$217M
$31.7M 0.79%
+1,499,682
New +$36.9M
CSOD
50
DELISTED
Cornerstone OnDemand, Inc.
CSOD
$30.6M 0.77%
+788,083
New +$32.5M

Similar funds

PFM Health Sciences's Q1 2017 Portfolio in Review

As of Q1 2017, PFM Health Sciences held 133 positions worth $3.99B, up 13% from $3.55B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

PFM Health Sciences withdrew a net $204M in Q1 2017, closing 37 positions and reducing 23 holdings. Its most notable exit was Range Resources, an estimated $86.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Communication Services.

Against the trend, PFM Health Sciences opened a new position in Liberty Global Class A worth $111M.

  • PFM Health Sciences's largest Q1 2017 buy was Liberty Global Class A: 3,089,161 shares worth $111M.
  • PFM Health Sciences added most to Marvell Technology in Q1 2017, an estimated $99.1M increase.
  • PFM Health Sciences's biggest Q1 2017 reduction was Cigna, cutting an estimated $69.3M.
  • PFM Health Sciences fully exited Range Resources in Q1 2017, selling an estimated $86.2M.
  • PFM Health Sciences's ten largest holdings make up 27% of its $3.99B portfolio in Q1 2017.
  • PFM Health Sciences opened 39 new positions and closed 37 in Q1 2017.
  • PFM Health Sciences's portfolio value rose 13% quarter-over-quarter to $3.99B.

Based on PFM Health Sciences's 13F filing for Q1 2017, filed 15 May 2017.